The startup specializes in the production of cell and viral-based therapeutics aimed at treating human diseases, utilizing advanced biotechnological methods to create targeted treatment options. This approach provides healthcare professionals with effective alternatives for patients who have limited treatment options available.
Funding
$7.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for producing cell and viral-based therapeutics are expensive and inefficient, which limits the availability of advanced treatment options for various human diseases. Poor oxygen transfer during cell growth restricts cell density, quality, and reproducibility, creating a bottleneck in biomedical research and manufacturing.
Solution
XDemics provides a patented High-Density Cell Respiration (HDCR™) technology that enhances cell and viral-based therapeutic production. The technology utilizes a gas-permeable membrane with a geometric design to create ideal replicative niches for cells, ensuring optimal oxygenation. This approach enables cells to thrive at densities 10-100X higher than traditional methods, significantly improving yield, quality, and efficiency. XDemics' solution streamlines workflows, reduces costs, and accelerates biomedical innovation from lab-scale research to industrial-scale production.
Target Audience
The primary target audience includes researchers in early hit to lead production, target production, high throughput screening, cell-based assays, protein engineering & design, immunology studies, CRISPR / gene editing, proteomics, genomics, and metabolomics, as well as manufacturers in gene therapy, T-cell, stem cell, biologics, TIL therapy, oncolytic virus, regenerative medicine, and exosome production.
Features
- Patented High-Density Cell Respiration (HDCR™) technology for enhanced oxygen transfer
- Gas-permeable membrane with geometric design to create ideal replicative niches
- Achieves 10-100X higher cell densities compared to traditional methods
- Expansify™ plates and trays for two-dimensional to three-dimensional cell growth transition
- Scalable from 24-well plates to 50L bioreactors with identical geometry and environment
- Streamlined process optimization with decreased risk, improved quality, and control
- Reduces hands-on time by 95% and improves productivity by 25X at the lab bench
- Enables an 80% cost decrease in cell and gene therapy manufacturing